Milestone achieved: Initiation of all clinical centers for
priMe trial completed

We are pleased to announce that with the completed initiation of all clinical trial centers, located in Kenya, Tanzania, Uganda, South Africa and Gabon, a major milestone in the pivotal phase III trial (priMe) of the novel tuberculosis vaccine VPM1002 has been accomplished.

We thank all consortium partners for the effort in achieving this important milestone and wish the clinical centers a good start!

Scroll to Top